Sulfonamido ether substituted imidazoquinolines
Assignee3M Innovative Properties Company
InventorsStephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
Life of this patent
Estimating the term…
Abstract
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Claims26
A compound of the formula (I):
- wherein:
- X is —CHR5—, —CHR5-alkyl-, or —CHR5-alkenyl-;
- R1 is selected from the group consisting of:
- —R4—NR3—SO2—R6-alkyl;
- —R4—NR3—SO2—R6-alkenyl;
- —R4—NR3—SO2—R6-aryl;
- —R4—NR3—SO2-R6-heteroaryl;
- —R4—NR3—SO2-R6-heterocyclyl;
- —R4—NR3—SO2-R7;
- —R4—NR3—SO2—NR5—R6-alkyl;
- —R4—NR3—SO2—NR5—R6-alkenyl;
- —R4—NR3—SO2—NR5—R6-aryl;
- —R4—NR3—SO2—NR5—R6-heteroaryl;
- —R4—NR3—SO2—NRs—R6-heterocyclyl;
- and
- —R4—NR3—SO2—NH2;
- R2 is selected from the group consisting of:
- -hydrogen;
- -alkyl;
- -alkenyl;
- -aryl;
- -heteroaryl;
- -heterocyclyl;
- -alkyl-Y-alkyl;
- -alkyl-Y-alkenyl;
- -alkyl-Y-aryl;
- and
- -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
- —OH;
- -halogen;
- —N(R5)2;
- —CO—N(R5)2;
- —CO—C1-10 alkyl;
- —CO—O—C1-10 alkyl;
- —N3;
- -aryl;
- -heteroaryl;
- -heterocyclyl;
- —CO-aryl;
- and
- —CO-heteroaryl;
- Y is —O— or —S(O)0-2—;
- R3 is H, C1-10 alkyl, or arylalkyl;
- each R4 is independently alkyl or alkenyl, which may be interrupted by one or more —O— groups;
- or R3 is C1-10 alkyl R3 and R4 can join together to form a piperidine ring;
- each R5 is independently H, C1-10 alkyl, or C2-10 alkenyl;
- R6 is a bond, alkyl, or alkenyl, which may be interrupted by one or more —O— groups;
- R7 is C1-10 alkyl;
- or R3 and R7 can join together to form a 5-membered heterocyclic ring;
- n is 0 to 4;
- and
- each R present is independently selected from the group consisting of C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen and trifluoromethyl;
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- N-(2-{2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)methanesulfonamide;
- N-(2-{2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)methanesulfonamide;
- N-(2-{2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)-N-methylmethanesulfonamide;
- N-(2-{2-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)-N-methylmethanesulfonamide;
- 2-butyl-1-{2-[2-(1,1-dioxidoisothiazolidin-2-yl)ethoxy]ethyl}-1H-imidazo[4,5-c]quinolin-4-amine;
- and
- N-[10-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)-4,7-dioxadecyl]-5-dimethylaminonaphthalene-1-sulfonamide;
- or a pharmaceutically acceptable salt thereof.
A compound of the formula (II)
- wherein:
- X is —CHR5—, —CHR5-alkyl-, or —CHR5-alkenyl-;
- R1 is selected from the group consisting of:
- —R4—NR3—SO2—R6-alkyl;
- —R4—NR3—SO2—R6-alkenyl;
- —R4—NR3—SO2—R6-aryl;
- —R4—NR3—SO2—R6-heteroaryl;
- —R4—NR3—SO2—R6-heterocyclyl;
- —R4—NR3—SO2—R7;
- —R4—NR3—SO2—NR5—R6-alkyl;
- —R4—NR3—SO2—NR5—R6-alkenyl;
- —R4—NR3—SO2—NR5—R6-aryl;
- —R4—NR3—SO2—NR5—R6-heteroaryl;
- —R4—NR3—SO2—NR5—R6-heterocyclyl;
- and
- —R4—NR3—SO2—NH2;
- R2 is selected from the group consisting of:
- -hydrogen;
- -alkyl;
- -alkenyl;
- -aryl;
- -heteroaryl;
- -heterocyclyl;
- -alkyl-Y-alkyl;
- -alkyl-Y-alkenyl;
- -alkyl-Y-aryl;
- and
- -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
- —OH;
- -halogen;
- —N(R5)2;
- —CO—N(R5)2;
- —CO—C1-10 alkyl;
- —CO—O—C1-10 alkyl;
- —N3;
- -aryl;
- -heteroaryl;
- -heterocyclyl;
- —CO-aryl;
- and
- —CO-heteroaryl;
- Y is —O— or —S(O)0-2—;
- R3 is H, C1-10 alkyl, or arylalkyl;
- each R4 is independently alkyl or alkenyl, which may be interrupted by one or more —O— groups;
- or when R3 is C1-10 alkyl R3 and R4 can join together to form a piperidine cyclic or ring;
- each R5 is independently H, C1-10 alkyl, or C2-10 alkenyl;
- R6 is a bond, alkyl, or alkenyl, which may be interrupted by one or more —O— groups;
- R7 is C1-10 alkyl;
- or when R3 is C1-10 alkyl R3 and R7 can join together to form a 5-membered heterocyclic ring;
- n is 0 to 4;
- and
- each R present is independently selected from the group consisting of C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen, and trifluoromethyl;
- or a pharmaceutically acceptable salt thereof.
A compound of the formula (III):
- wherein
- X is —CHR5—, —CHR5-alkyl-, or —CHR5-alkenyl-;
- R1 is selected from the group consisting of:
- —R4—NR3—SO2—R6-alkyl;
- —R4—NR3—SO2—R6-alkenyl;
- —R4—NR3—SO2—R6-aryl;
- —R4—NR3—SO2—R6-heteroaryl;
- —R4—NR3—SO2—R6-heterocyclyl;
- —R4—NR3—SO2—R7;
- —R4—NR3—SO2—NR5—R6-alkyl;
- —R4—NR3—SO2—NR5—R6-alkenyl;
- —R4—NR3—SO2—NR5—R6-aryl;
- —R4—NR3—SO2—NR5—R6-heteroaryl;
- —R4—NR3—SO2—NR5—R6-heterocyclyl;
- and
- —R4—NR3—SO2—NH2;
- R2 is selected from the group consisting of:
- -hydrogen;
- -alkyl;
- -alkenyl;
- -aryl;
- -heteroaryl;
- -heterocyclyl;
- -alkyl-Y-alkyl;
- -alkyl-Y-alkenyl;
- -alkyl-Y-aryl;
- and
- -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
- —OH;
- -halogen;
- —N(R5)2;
- —CO—N(R5)2;
- —CO—C1-10 alkyl;
- —CO—O—C1-10 alkyl;
- —N3;
- -aryl;
- -heteroaryl;
- -heterocyclyl;
- —CO-aryl;
- and
- —CO-heteroaryl;
- Y is —O— or —S(O)0-2—;
- R3 is H, C1-10 alkyl, or arylalkyl;
- each R4 is independently alkyl or alkenyl, which may be interrupted by one or more —O— groups;
- or when R3 is C1-10 alkyl R4 and R3 can join to form a piperidine ring;
- each R5 is independently H, C1-10 alkyl, or C2-10 alkenyl;
- R6 is a bond, or is alkyl or alkenyl, which may be interrupted by one or more —O— groups;
- R7 is C1-10 alkyl;
- or when R3 is C1-10 alkyl R3 and R7 can join together to form a 5-membered heterocyclic ring;
- n is 0 to 4;
- and
- each R present is independently selected from the group consisting of C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen and trifluoromethyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.